Whereas FLT3 plays a key role in leukemogenesis in about 30% of AML patients [6,7], Src-family kinases, which are downstream of FLT3, are over-expressed in AML and collaborate with FLT3 to facilitate AML progression [46]. This evidence concerns the gene FLT3 and acute myeloid leukemia.